Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Sequential tamoxifen-anastrozole treatment trialled

By News team

Relapse-free survival is not significantly improved by sequential tamoxifen and anastrazole treatment, rather than continuous tamoxifen, for oestrogen receptor-positive breast cancer, new research confirms.

In the study, published online in the Journal of Clinical Oncology (23 January 2012), postmenopausal women were randomly assigned to receive either five years of tamoxifen (n=1,849) or two years of tamoxifen followed by three years of anastrazole (n=1,865).

Sequential treatment was associated with a 20 per cent decrease in risk of recurrence compared with tamoxifen treatment only, but the effect was not statistically significant. No clear differences were seen in the side effect profiles of the treatment approaches.

Advertisement

Citation: The Pharmaceutical JournalURI: 11094347

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free newsletters.